France· FR:62689214
KEYTRUDA 25 mg/mL, solution à diluer pour perfusion
A medicinal product containing pembrolizumab, registered in France by MERCK SHARP & DOHME (PAYS-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PEMBROLIZUMAB
- Manufacturer
- MERCK SHARP & DOHME (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009550243161 flacon(s) en verre de 4 ml
- cip1334009551048652 flacon(s) en verre de 4 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pembrolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsKeytruda 25 mg/ml concentraat voor oplossing voor infusieMerck Sharp & Dohme B.V.
- United KingdomKeytruda 100mg/4ml concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- SpainKEYTRUDA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandKeytrudaMerck Sharp & Dohme B.V.
- BelgiumKeytruda 25 mg/mlMerck Sharp & Dohme
- CzechiaKEYTRUDAMerck Sharp & Dohme B.V., Haarlem
- IrelandKEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV,
- SwedenKEYTRUDA 25 mg/ml Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Keytruda
- Liechtenstein · Keytruda
- Norway · Keytruda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a4419153-3500-409a-ac42-531d39df1796 GET /v1/drugs/a4419153-3500-409a-ac42-531d39df1796?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62689214",
"date_amm": "2016-08-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1024",
"substance": "PEMBROLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about pembrolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.